Mbx Biosciences Inc: 5%+ holders

As of November 9, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Mbx Biosciences Inc. The largest reported stake is Fmr LLC's, at 15%. 23 filings are on record since August 12, 2025 (Schedule 13G/A, November 5, 2026).

Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. also filed stake reports on 2 other companies ↓

Sell to companies like Mbx Biosciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-05 · Reporting person: Fmr LLC · Sole voting: 7,211,235 · Shared voting: 0 · Sole dispositive: 7,224,009 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
• Filed 2026-08-14 · Holder: Deep Track Capital, LP · Percent: 3.64% · SCHEDULE 13G/A
• Filing 2026-08-10 · Reporting person: Frazier Life Sciences Public Fund, L.P. · Sole voting: 0 · Shared voting: 1,429,573 · Sole dispositive: 0 · Shared dispositive: 1,429,573 · SCHEDULE 13D/A, 2026-08-10
• Filing 2026-08-10 · Reporting person: Orbimed Advisors LLC · Sole voting: 0 · Shared voting: 3,074,853 · Sole dispositive: 0 · Shared dispositive: 3,074,853 · SCHEDULE 13D/A, 2026-08-10
• Filing 2026-07-29 · Reporting person: BlackRock, Inc. · Sole voting: 2,583,923 · Shared voting: 0 · Sole dispositive: 2,628,181 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-29

Mbx Biosciences Inc has 23 Schedule 13D or 13G filings on record since 2025-08-12. 7 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Mbx Biosciences Inc and the warning signs.

See Mbx Biosciences Inc's free Snapshot Watch Mbx Biosciences Inc: email me the next time it files something

Free to see. No signup.

Keep reading

More on Mbx Biosciences Inc and the records around it.

Mbx Biosciences Inc elsewhere on the record

• Leadership changes Jul 2026
• IPO filing Sep 2025
• Who owns it

Companies that share a holder

• Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. also filed stake reports on 2 other companies: Korsana Biosciences, Inc. (Sep 2026), ProMIS Neurosciences, Inc. (Aug 2026)
• New Enterprise Associates 17, L.P. also filed stake reports on 4 other companies: Monte Rosa Therapeutics, Inc. (Jul 2026), Inventiva S.A. (Apr 2026), Korro Bio, Inc. (Mar 2026)
• Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)

Want the whole picture on Mbx Biosciences Inc?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Mbx Biosciences Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Mbx Biosciences Inc covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   30 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Mbx Biosciences Inc by CUSIP 55287L101 and gives its principal executive office as 11711 N. MERIDIAN STREET, SUITE 300, CARMEL, IN 46032 (SCHEDULE 13G/A, 2026-11-05).

What the percentages are based on

See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 47,597,536 shares of Common Stock outstanding as of May 4, 2026, as reported by the Issuer in its Form 10-Q filed with the SEC on May 7, 2026.Paradigm BioCapital Advisors LP, SCHEDULE 13G, 2026-06-24

Source of funds (Item 3)

Item 3 of the Schedule 13D is hereby amended to incorporate Item 5(c) hereof and to replace the last paragraph with the following: The working capital of FLSPF, FLS X and FLS XI was the source of the funds for the purchase of the FLSPF Shares, the FLS X Shares and the FLS XI Shares. No part of the purchase price of the FLSPF Shares, the FLS X Shares or the FLS XI Shares was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the FLSPF Shares, the FLS X Shares or the FLS XI Shares.Frazier Life Sciences Public Fund, L.P., SCHEDULE 13D/A, 2026-08-10

Not applicable.Orbimed Advisors LLC, SCHEDULE 13D/A, 2026-08-10

Purpose of Transaction (Item 4)

Frazier Life Sciences Public Fund, L.P.

Item 4 is hereby amended to remove references to "FLSPOF" and the "FLSPOF Shares" from the first paragraph.Item 4 of the SCHEDULE 13D/A filed 2026-08-10

Orbimed Advisors LLC

The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-08-10; the filing has the rest

New Enterprise Associates 17, L.P.

NEA 17 acquired the NEA 17 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 17 and the other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-10; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Mbx Biosciences Inc

Who owns Mbx Biosciences Inc?

On this page, 7 holders' latest ownership filings report 5% or more of Mbx Biosciences Inc: Fmr LLC (15%, Schedule 13G/A, filed 2026-11-05), Frazier Life Sciences Public Fund, L.P. (11.7%, Schedule 13D/A, filed 2026-08-10), Wellington Management Group LLP (10.5%, Schedule 13G/A, filed 2026-07-08), New Enterprise Associates 17, L.P. (8.1%, Schedule 13D/A, filed 2025-11-10) and Orbimed Advisors LLC (6.4%, Schedule 13D/A, filed 2026-08-10); 2 more are listed above.

Who are the largest shareholders of Mbx Biosciences Inc?

By the share each holder's latest filing reports, the largest holders of Mbx Biosciences Inc on this page are Fmr LLC (15%), Frazier Life Sciences Public Fund, L.P. (11.7%) and Wellington Management Group LLP (10.5%).

When did Fmr LLC buy into Mbx Biosciences Inc?

The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-05-06, reporting 6.2%; its latest, Schedule 13G/A filed 2026-11-05, reports 15%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 23 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Mbx Biosciences Inc

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Mbx Biosciences Inc. With no account yet, you sign up free and land on the result.

• Get an alert when Mbx Biosciences Inc is mentioned again
• Find former Mbx Biosciences Inc employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes